Ocuvex Therapeutics

Ocuvex Therapeutics is a San Diego-based ophthalmology company founded in 2020, specializing in biologics and antibodies. The company has transitioned from a development-stage entity to one with a commercial product, OMLONTI®, for glaucoma, and is pursuing a pipeline targeting conditions like post-surgical inflammation. In a significant strategic move, Ocuvex has entered into a definitive merger agreement with publicly traded Onconetix, Inc., which upon closing will provide public market access and result in Ocuvex shareholders owning 90% of the combined company.

Strategic business development and commercialization platform focused on identifying, acquiring, and developing innovative ophthalmic therapeutics, with a focus on biologics and antibodies.

The glaucoma market is highly competitive with numerous established pharmaceuticals and novel therapies. The post-surgical inflammation market also has several existing players. Ocuvex's strategy to compete appears based on acquiring/developing innovative products with differentiated mechanisms (e.g., dual action) and leveraging strategic commercial execution.